Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 3 years
- Director since
- 2023
3 years of board service in total across 1 board, counting each seat separately. Longest: Fennec Pharmaceuticals Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Fennec Pharmaceuticals Inc. June 12, 202399.6%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Apr 22, 2024 | Fennec Pharmaceuticals Inc. | Option exercise | +22,223 | $2.31 | $51,335 |
| Apr 22, 2024 | Fennec Pharmaceuticals Inc. | Open-market sale | −22,223 | $9.32 | $207,118 |
| Apr 19, 2024 | Fennec Pharmaceuticals Inc. | Option exercise | +22,222 | $2.31 | $51,333 |
| Apr 19, 2024 | Fennec Pharmaceuticals Inc. | Open-market sale | −22,222 | $9.34 | $207,553 |
| Apr 18, 2024 | Fennec Pharmaceuticals Inc. | Open-market sale | +22,222 | $2.31 | $51,333 |
| Apr 18, 2024 | Fennec Pharmaceuticals Inc. | Open-market sale | −22,222 | $9.62 | $213,776 |
| Apr 17, 2024 | Fennec Pharmaceuticals Inc. | Open-market sale | +22,222 | $2.31 | $51,333 |
| Apr 17, 2024 | Fennec Pharmaceuticals Inc. | Open-market sale | −22,222 | $9.91 | $220,220 |
| Apr 16, 2024 | Fennec Pharmaceuticals Inc. | Open-market sale | +22,222 | $2.31 | $51,333 |
| Apr 16, 2024 | Fennec Pharmaceuticals Inc. | Open-market sale | −22,222 | $10.28 | $228,442 |
| Apr 15, 2024 | Fennec Pharmaceuticals Inc. | Open-market sale | +22,222 | $2.31 | $51,333 |
| Apr 15, 2024 | Fennec Pharmaceuticals Inc. | Open-market sale | −22,222 | $10.30 | $228,887 |
Questions about Adrian Haigh
What boards is Adrian Haigh on?
Adrian Haigh sits on the board of Fennec Pharmaceuticals Inc.
How long has Adrian Haigh served on boards?
Our records show at least 3 years of board service across 1 board, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.